Welcome to our dedicated page for Danaher Corporation SEC filings (Ticker: DHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Danaher’s 10-K can exceed 250 pages, weaving life-sciences revenue, diagnostics margins, and dozens of recent acquisitions into dense footnotes. Finding how Cytiva lifted bioprocessing sales or when executives exercise options is time-consuming. Stock Titan decodes every Danaher SEC filing, turning complexity into clarity.
Our platform delivers AI-powered summaries that make Danaher SEC filings explained simply. Need the latest Danaher quarterly earnings report 10-Q filing? We tag segment performance so you can compare consumables growth quarter-over-quarter. Tracking governance? Get Danaher proxy statement executive compensation highlights in plain English. Material event on a new acquisition? See the Danaher 8-K material events explained the moment it posts to EDGAR. And because insider activity moves the stock, our alerts surface Danaher insider trading Form 4 transactions—including Danaher Form 4 insider transactions real-time—before the market digests them.
Investors use these insights to:
- Monitor R&D intensity versus peers with Danaher annual report 10-K simplified
- Spot integration costs from recent M&A using Danaher earnings report filing analysis
- Review Danaher executive stock transactions Form 4 ahead of earnings calls
- Understand environmental disclosures and DBS efficiency metrics without reading every footnote
Whether you’re understanding Danaher SEC documents with AI for strategic research or scanning for trading catalysts, Stock Titan provides real-time updates, expert context, and the confidence to act on every disclosure.
Danaher Corporation is providing an early look at its financial performance, sharing estimated results for the fourth quarter of 2025 and for full-year 2025. On January 12, 2026, the company issued a press release and presentation slides in connection with a public webcast at the J.P. Morgan Healthcare Conference on January 13, 2026. These materials, furnished under a current report, outline management’s view of recent performance and are incorporated by reference as exhibits, but are expressly designated as furnished rather than filed under securities law.
Danaher Corporation director and executive Mitchell P. Rales increased his deferred stock-based holdings through a plan contribution. On 12/30/2025, he acquired 1,543.981 derivative interests tied to Danaher common stock through the Danaher Deferred Compensation Plan’s Danaher Stock Fund.
The contribution is recorded as notional shares that track Danaher common stock on a one-for-one basis, with an exercise price of $0.00 and a reference price of $230.67 per share. Following this transaction, Rales held 7,969.204 derivative securities linked to Danaher stock in this plan. All deferrals in this stock fund are described as immediately vested, meaning the economic rights tied to these notional shares are fully earned when contributed.
Danaher Corp. (DHR) director and officer Mitchell P. Rales reported selling common stock in the company. On November 25, 2025, a family trust for which he serves as trustee sold 35,899 shares at a weighted average price of $230.27 and 4,726 shares at a weighted average price of $231.19.
After these transactions, the Mitchell P. Rales Family Trust held 850,000 Danaher shares. Rales also has additional beneficial holdings, including 553,228 shares held directly, shares in a 401(k) plan, shares in custodial accounts for his daughter (for which he disclaims beneficial ownership), and 25,671,000 shares held through single-member LLCs owned by a revocable trust of which he is sole trustee and beneficiary.
Danaher (DHR)Mitchell P. Rales filed a Rule 144 notice covering the planned sale of 40,625 shares of common stock through broker Monness, Crespi, Hardt & Co., Inc. on or about 11/25/2025, with an aggregate market value of $9,221,063. The filing notes that 706,349,563 shares of Danaher common stock were outstanding for context and that the shares are listed on the NYSE.
The securities to be sold were originally acquired on 06/11/2021 as part of a distribution from closely held Capital Yield Corporation, totaling 1,900,000 shares, with no cash payment due to the liquidation of that corporation. Over the past three months, Rales has already sold 600,000 shares of Danaher common stock on 10/31/2025 for gross proceeds of $129,635,820 and a further 437,000 shares on 11/12/2025 for gross proceeds of $95,566,167.
By signing the notice, the seller represents that he is not aware of any undisclosed material adverse information about Danaher’s current or prospective operations.
Danaher Corporation has a notice for the potential sale of 146,957 shares of common stock through broker Monness, Crespi, Hardt & Co., Inc. on the NYSE. The shares have an indicated aggregate market value of $33,356,300 based on the information provided, with 706,349,563 shares outstanding of this class. The approximate sale date listed is 11/25/2025.
The shares to be sold were acquired as common stock via a gift from affiliate Mitchell P. Rales on 06/11/2021, with the donor’s original acquisition date of 12/16/1983. The consideration is described as "None - gift to foundation", indicating the securities were transferred to a foundation rather than purchased for cash.
Danaher Corporation (DHR) director and officer Mitchell P. Rales reported an insider transaction involving Danaher common stock. On 11/25/2025, a family trust for which he serves as trustee transferred 22,029 shares of common stock as a gift at a reported price of $0. Following this transaction, that family trust held 890,625 shares indirectly.
In addition, Rales is shown as holding 553,228 shares directly, 667 shares through a 401(k) plan, and 3,256 shares in custodial accounts for his daughter, for which he disclaims beneficial ownership. A further 25,671,000 shares are held indirectly through single-member LLCs owned by a revocable trust of which he is sole trustee and beneficiary.
Danaher Corporation director Form 4 filing reports an option exercise and share sale. On 11/18/2025, a director exercised a stock option for 3,298 shares of Danaher common stock at an exercise price of $71.88 per share. That same day, the director sold 3,298 shares of common stock at a price of $226.50 per share. After these transactions, the director beneficially owned 20,761.994 shares of Danaher common stock held directly.
Danaher Corporation (DHR)
Danaher Corporation (DHR) reported new equity awards to its Senior Vice President and General Counsel, Jonathan Leiken. On November 15, 2025, he received 10,172 restricted stock units (RSUs)$0 per share. One third of these RSUs vest on each of the first, second, and third anniversaries of the grant date. On the same date, he was also granted an employee stock option to purchase 26,767 shares of common stock at an exercise price of $221.21 per share, with one third of the options becoming exercisable on each of the first three anniversaries of November 15, 2025.
Danaher Corporation (DHR)11/15/2025, Milosevich disposed of 35 shares of Danaher common stock at a price of $221.21 per share in a transaction coded "F," which typically reflects shares withheld to cover taxes on equity awards. Following this small transaction, he directly beneficially owns 4,420 shares of Danaher common stock. No derivative securities transactions were reported.
FAQ
What is the current stock price of Danaher Corporation (DHR)?
What is the market cap of Danaher Corporation (DHR)?
